Pomalyst is the latest of a half-dozen myeloma drugs developed in the decade or so since Wright got diagnosed. Another, called Kyprolis, won FDA approval last summer.
Like many so-called "targeted" cancer therapies coming out these days, the new drugs are enormously expensive. Pomalyst will cost about $10,450 a month, or more than $125,000 a year.
Dr. Brian Durie of the International Myeloma Foundation says the availability of these new drugs has been transformative.
"It really has changed the whole landscape for both the doctor and the patient," he says. "Ten or 15 years ago, it was very depressing to see a new myeloma patient because you knew that the life was potentially short and it was difficult to be overly optimistic about what might transpire."
Read more.
No comments:
Post a Comment